Treatment of Relapsed/Refractory Anaplastic Large Cell Lymphoma with Brentuximab Vedotin

This is a clinical practice guideline for the treatment of relapsed/refractory anaplastic large cell lymphoma. The guideline facilitates the safe and effective clinical use of brentuximab vedotin. The treatment intent is non-curative and to improve progression-free survival and overall survival.